Imidazopyridazine Acetylcholinesterase Inhibitors Display Potent Anti-Proliferative Effects in the Human Neuroblastoma Cell-Line, IMR-32
Abstract
:1. Introduction
2. Results
2.1. Substituted Imidazo[1,2-b]pyridazine Compounds Differentially Affect Cell Viability
2.2. Substituted Imidazo[1,2-b]pyridazine Compounds Affect Proliferation of IMR-32 Cells
2.3. Substituted Imidazo[1,2-b]pyridazine Compounds Alter Cell Cycle Progression
2.4. Compounds 5c and 5h Increase Mitochondrial Stress in IMR-32 Cells
2.5. Substituted Imidazo[1,2-b]pyridazine Compounds Affect IMR-32 Cell Migration
2.6. Substituted Imidazo[1,2-b]pyridazine Compounds Exhibit Anti-inflammatory Properties
3. Discussion
4. Materials and Methods
4.1. Synthesis of the Compounds
4.2. Cell Culture and Reagents
4.3. Cell Viability and Apoptosis Assays
4.4. Cell Cycle Analysis
4.5. Cell Proliferation Assays
4.6. Cell Migration Assay
4.7. Western Blotting
4.8. Mitochondrial Oxidative Stress Analysis
4.9. Cellular ATP and Released Nitrate Estimation
4.10. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Sample Availability
References
- Bishop, N.A.; Lu, T.; Yankner, B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464, 529–535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartus, R.T.; Dean, R.L., 3rd; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408–414. [Google Scholar] [CrossRef] [PubMed]
- Pope, C.N.; Brimijoin, S. Cholinesterases and the fine line between poison and remedy. Biochem. Pharmacol. 2018, 153, 205–216. [Google Scholar] [CrossRef]
- McHardy, S.F.; Wang, H.L.; McCowen, S.V.; Valdez, M.C. Recent advances in acetylcholinesterase Inhibitors and Reactivators: An update on the patent literature (2012–2015). Expert Opin. Pat. 2017, 27, 455–476. [Google Scholar] [CrossRef]
- Mehta, M.; Adem, A.; Sabbagh, M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int. J. Alzheimers Dis. 2012, 2012, 728983. [Google Scholar] [CrossRef]
- Galimberti, D.; Scarpini, E. Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opin. Investig. Drugs 2016, 25, 1181–1187. [Google Scholar] [CrossRef]
- Winblad, B.; Giacobini, E.; Frolich, L.; Friedhoff, L.T.; Bruinsma, G.; Becker, R.E.; Greig, N.H. Phenserine efficacy in Alzheimer’s disease. J. Alzheimers Dis. 2010, 22, 1201–1208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Becker, R.E.; Greig, N.H. Was phenserine a failure or were investigators mislead by methods? Curr. Alzheimer Res. 2012, 9, 1174–1181. [Google Scholar] [CrossRef]
- De Souza, L.G.; Renna, M.N.; Figueroa-Villar, J.D. Coumarins as cholinesterase inhibitors: A review. Chem. Biol. Interact. 2016, 254, 11–23. [Google Scholar] [CrossRef] [PubMed]
- Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: A dual function lead for Alzheimer’s disease therapy. J. Med. Chem. 2003, 46, 2279–2282. [Google Scholar] [CrossRef] [PubMed]
- Shen, Q.; Peng, Q.; Shao, J.; Liu, X.; Huang, Z.; Pu, X.; Ma, L.; Li, Y.M.; Chan, A.S.; Gu, L. Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2005, 40, 1307–1315. [Google Scholar] [CrossRef]
- Singh, A.; Sharma, S.; Arora, S.; Attri, S.; Kaur, P.; Kaur Gulati, H.; Bhagat, K.; Kumar, N.; Singh, H.; Vir Singh, J.; et al. New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation. Bioorg. Med. Chem. Lett. 2020, 30, 127477. [Google Scholar] [CrossRef]
- Luraschi, E.; Arena, F.; Sacchi, A.; Laneri, S.; Abignente, E.; Avallone, L.; D’Amico, M.; Berrino, L.; Rossi, F. Research on heterocyclic compounds. XXXVIII. Synthesis and pharmacological activity of imidazo[1,2-b]pyridazine-2-carboxylic derivatives. Farmaco 1997, 52, 213–217. [Google Scholar]
- Luraschi, E.; Arena, F.; Sacchi, A.; Laneri, S.; Abignente, E.; D’Amico, M.; Berrino, L.; Rossi, F. Research on heterocyclic compounds. XXXIII--Synthesis and analgesic activity of imidazo[1,2-b]pyridazine-2-acetic acid derivatives. Farmaco 1995, 50, 349–354. [Google Scholar]
- Sridhar, P.; Alagumuthu, M.; Ram, B.; Arumugam, S.; Reddy, S.R. Drugs Against Neurodegenerative Diseases: Design and Synthesis of 6-Amino-substituted Imidazo[1,2-b]pyridazines as Acetylcholinesterase Inhibitors. Chem. Sel. 2017, 2, 842–847. [Google Scholar] [CrossRef]
- Kandimalla, R.J.; Wani, W.Y.; Binukumar, B.K.; Gill, K.D. siRNA against presenilin 1 (PS1) down regulates amyloid beta42 production in IMR-32 cells. J. Biomed. Sci. 2012, 19, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.; Chang, Q. MicroRNA miR-212 regulates PDCD4 to attenuate Abeta25-35-induced neurotoxicity via PI3K/AKT signaling pathway in Alzheimer’s disease. Biotechnol. Lett. 2020, 42, 1789–1797. [Google Scholar] [CrossRef]
- Clementi, M.E.; Tringali, G.; Triggiani, D.; Giardina, B. Aloe arborescens Extract Protects IMR-32 Cells against Alzheimer Amyloid Beta Peptide via Inhibition of Radical Peroxide Production. Nat. Prod. Commun. 2015, 10, 1993–1995. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asthana, A.; Bollapalli, M.; Tangirala, R.; Bakthisaran, R.; Mohan Rao, C. Hsp27 suppresses the Cu(2+)-induced amyloidogenicity, redox activity, and cytotoxicity of alpha-synuclein by metal ion stripping. Free Radic. Biol. Med. 2014, 72, 176–190. [Google Scholar] [CrossRef] [PubMed]
- Sharma, R.K.; Candelario-Jalil, E.; Feineis, D.; Bringmann, G.; Fiebich, B.L.; Akundi, R.S. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) Alters Cell Cycle Progression in Human Neuroblastoma Cell Lines. Neurotox. Res. 2017, 32, 649–660. [Google Scholar] [CrossRef] [PubMed]
- Gupta, M.; Notter, M.F.; Felten, S.; Gash, D.M. Differentiation characteristics of human neuroblastoma cells in the presence of growth modulators and antimitotic drugs. Brain Res. 1985, 351, 21–29. [Google Scholar] [CrossRef]
- Khaw, K.Y.; Kumar, P.; Yusof, S.R.; Ramanathan, S.; Murugaiyah, V. Probing simple structural modification of alpha-mangostin on its cholinesterase inhibition and cytotoxicity. Arch. Pharm. 2020, 353, e2000156. [Google Scholar] [CrossRef]
- Khan, M.I.; Shin, J.H.; Kim, M.Y.; Shin, T.S.; Kim, J.D. Green Tea Seed Isolated Theasaponin E1 Ameliorates AD Promoting Neurotoxic Pathogenesis by Attenuating Abeta Peptide Levels in SweAPP N2a Cells. Molecules 2020, 25, 2334. [Google Scholar] [CrossRef]
- Li, Q.; Wu, D.; Zhang, L.; Zhang, Y. Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. Exp. Gerontol. 2010, 45, 842–847. [Google Scholar] [CrossRef]
- Chaves, S.; Resta, S.; Rinaldo, F.; Costa, M.; Josselin, R.; Gwizdala, K.; Piemontese, L.; Capriati, V.; Pereira-Santos, A.R.; Cardoso, S.M.; et al. Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease. Molecules 2020, 25, 985. [Google Scholar] [CrossRef] [Green Version]
- Cortes-Gomez, M.A.; Llorens-Alvarez, E.; Alom, J.; Del Ser, T.; Avila, J.; Saez-Valero, J.; Garcia-Ayllon, M.S. Tau phosphorylation by glycogen synthase kinase 3beta modulates enzyme acetylcholinesterase expression. J. Neurochem. 2021, 157, 2091–2105. [Google Scholar] [CrossRef] [PubMed]
- Xu, T.; Xie, H.Q.; Li, Y.; Xia, Y.; Sha, R.; Wang, L.; Chen, Y.; Xu, L.; Zhao, B. Dioxin induces expression of hsa-miR-146b-5p in human neuroblastoma cells. J. Environ. Sci. 2018, 63, 260–267. [Google Scholar] [CrossRef]
- Curtin, B.F.; Pal, N.; Gordon, R.K.; Nambiar, M.P. Forskolin, an inducer of cAMP, up-regulates acetylcholinesterase expression and protects against organophosphate exposure in neuro 2A cells. Mol. Cell Biochem. 2006, 290, 23–32. [Google Scholar] [CrossRef] [PubMed]
- Durcan, N.; Costello, R.W.; McLean, W.G.; Blusztajn, J.; Madziar, B.; Fenech, A.G.; Hall, I.P.; Gleich, G.J.; McGarvey, L.; Walsh, M.T. Eosinophil-mediated cholinergic nerve remodeling. Am. J. Respir. Cell Mol. Biol. 2006, 34, 775–786. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ween, H.; Thorin-Hagene, K.; Andersen, E.; Gronlien, J.H.; Lee, C.H.; Gopalakrishnan, M.; Malysz, J. Alpha3* and alpha 7 nAChR-mediated Ca2+ transient generation in IMR-32 neuroblastoma cells. Neurochem. Int. 2010, 57, 269–277. [Google Scholar] [CrossRef] [PubMed]
- Akundi, R.S.; Macho, A.; Munoz, E.; Lieb, K.; Bringmann, G.; Clement, H.W.; Hull, M.; Fiebich, B.L. 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH. J. Neurochem. 2004, 91, 263–273. [Google Scholar] [CrossRef]
- Franken, N.A.; Rodermond, H.M.; Stap, J.; Haveman, J.; van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1, 2315–2319. [Google Scholar] [CrossRef]
- Jones, L.J.; Gray, M.; Yue, S.T.; Haugland, R.P.; Singer, V.L. Sensitive determination of cell number using the CyQUANT cell proliferation assay. J. Immunol. Methods 2001, 254, 85–98. [Google Scholar] [CrossRef]
- Sherr, C.J.; Roberts, J.M. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501–1512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akundi, R.S.; Rivkees, S.A. Hypoxia alters cell cycle regulatory protein expression and induces premature maturation of oligodendrocyte precursor cells. PLoS ONE 2009, 4, e4739. [Google Scholar] [CrossRef] [Green Version]
- Jiang, R.; Xue, S.; Jin, Z. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem. Biophys. Res. Commun. 2011, 410, 364–370. [Google Scholar] [CrossRef] [PubMed]
- Hardie, D.G. The AMP-activated protein kinase pathway--new players upstream and downstream. J. Cell Sci. 2004, 117, 5479–5487. [Google Scholar] [CrossRef] [Green Version]
- Martinez-Vicente, M. Neuronal Mitophagy in Neurodegenerative Diseases. Front. Mol. Neurosci. 2017, 10, 64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, S.; Kalra, H.; Akundi, R.S. Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase. Front. Pharmacol. 2020, 11, 617211. [Google Scholar]
- Fujimi, K.; Noda, K.; Sasaki, K.; Wakisaka, Y.; Tanizaki, Y.; Iida, M.; Kiyohara, Y.; Kanba, S.; Iwaki, T. Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer’s disease: The Hisayama Study. Dement. Geriatr. Cogn. Disord. 2007, 23, 423–431. [Google Scholar] [CrossRef]
- Akundi, R.S.; Candelario-Jalil, E.; Hess, S.; Hull, M.; Lieb, K.; Gebicke-Haerter, P.J.; Fiebich, B.L. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia 2005, 51, 199–208. [Google Scholar] [CrossRef]
- Fiebich, B.L.; Akter, S.; Akundi, R.S. The two-hit hypothesis for neuroinflammation: Role of exogenous ATP in modulating inflammation in the brain. Front. Cell Neurosci. 2014, 8, 260. [Google Scholar] [CrossRef] [Green Version]
- Lieb, K.; Engels, S.; Fiebich, B.L. Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem. Int. 2003, 42, 131–137. [Google Scholar] [CrossRef]
- Nakamura, T.; Tu, S.; Akhtar, M.W.; Sunico, C.R.; Okamoto, S.; Lipton, S.A. Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron 2013, 78, 596–614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lazarevic-Pasti, T.; Leskovac, A.; Momic, T.; Petrovic, S.; Vasic, V. Modulators of Acetylcholinesterase Activity: From Alzheimer’s Disease to Anti-Cancer Drugs. Curr. Med. Chem. 2017, 24, 3283–3309. [Google Scholar] [CrossRef]
- Iwasaki, T.; Yoneda, M.; Nakajima, A.; Terauchi, Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern. Med. 2007, 46, 1633–1639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pohanka, M. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int. J. Mol. Sci. 2014, 15, 9809–9825. [Google Scholar] [CrossRef] [Green Version]
- Chatterjee, P.K.; Al-Abed, Y.; Sherry, B.; Metz, C.N. Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am. J. Physiol. Cell Physiol. 2009, 297, C1294–C1306. [Google Scholar] [CrossRef] [Green Version]
- Visscher, D.W.; Pankratz, V.S.; Santisteban, M.; Reynolds, C.; Ristimaki, A.; Vierkant, R.A.; Lingle, W.L.; Frost, M.H.; Hartmann, L.C. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J. Natl. Cancer Inst. 2008, 100, 421–427. [Google Scholar] [CrossRef] [Green Version]
- Buchanan, F.G.; Holla, V.; Katkuri, S.; Matta, P.; DuBois, R.N. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67, 9380–9388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-. Nat. Rev. Cancer 2001, 1, 11–21. [Google Scholar] [CrossRef] [PubMed]
- Hudacova, M.; Hamulakova, S.; Konkolova, E.; Jendzelovsky, R.; Vargova, J.; Sevc, J.; Fedorocko, P.; Soukup, O.; Janockova, J.; Ihnatova, V.; et al. Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells. Int. J. Mol. Sci. 2021, 22, 3830. [Google Scholar] [CrossRef]
- Syed, M.; Fenoglio-Preiser, C.; Skau, K.A.; Weber, G.F. Acetylcholinesterase supports anchorage independence in colon cancer. Clin. Exp. Metastasis 2008, 25, 787–798. [Google Scholar] [CrossRef] [PubMed]
- Deng, R.; Li, W.; Guan, Z.; Zhou, J.M.; Wang, Y.; Mei, Y.P.; Li, M.T.; Feng, G.K.; Huang, W.; Liu, Z.C.; et al. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene 2006, 25, 7070–7077. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.; Sohn, E.J.; Yoon, S.W.; Kim, C.G.; Lee, S.; Kim, J.Y.; Baek, N.; Kim, S.H. Anti-Metastatic Effect of Dehydrocorydaline on H1299 Non-Small Cell Lung Carcinoma Cells via Inhibition of Matrix Metalloproteinases and B Cell Lymphoma. Phytother. Res. 2017, 31, 441–448. [Google Scholar] [CrossRef]
- Pfitzinger, P.L.; Fangmann, L.; Wang, K.; Demir, E.; Gurlevik, E.; Fleischmann-Mundt, B.; Brooks, J.; D’Haese, J.G.; Teller, S.; Hecker, A.; et al. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. J. Exp. Clin. Cancer Res. 2020, 39, 289. [Google Scholar] [CrossRef]
- Perry, C.; Sklan, E.H.; Birikh, K.; Shapira, M.; Trejo, L.; Eldor, A.; Soreq, H. Complex regulation of acetylcholinesterase gene expression in human brain tumors. Oncogene 2002, 21, 8428–8441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barbosa, M.; Rios, O.; Velasquez, M.; Villalobos, J.; Ehrmanns, J. Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors. Surg. Neurol. 2001, 55, 106–112. [Google Scholar] [CrossRef]
- Friedman, J.R.; Richbart, S.D.; Merritt, J.C.; Brown, K.C.; Nolan, N.A.; Akers, A.T.; Lau, J.K.; Robateau, Z.R.; Miles, S.L.; Dasgupta, P. Acetylcholine signaling system in progression of lung cancers. Pharmacol. Ther. 2019, 194, 222–254. [Google Scholar] [CrossRef]
- Qavi, H.; Al-Rajhi, A.A. Acetylcholinesterase and HHV-8 in squamous cell carcinoma and retinoblastoma. In Vivo 2009, 23, 679–683. [Google Scholar] [PubMed]
- Karpel, R.; Ben Aziz-Aloya, R.; Sternfeld, M.; Ehrlich, G.; Ginzberg, D.; Tarroni, P.; Clementi, F.; Zakut, H.; Soreq, H. Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp. Cell Res. 1994, 210, 268–277. [Google Scholar] [CrossRef]
- Vidal, C.J. Expression of cholinesterases in brain and non-brain tumours. Chem. Biol. Interact. 2005, 157–158, 227–232. [Google Scholar] [CrossRef] [PubMed]
- Price, D.; Muterspaugh, R.; Clegg, B.; Williams, A.; Stephens, A.; Guthrie, J.; Heyl, D.; Evans, H.G. IGFBP-3 Blocks Hyaluronan-CD44 Signaling, Leading to Increased Acetylcholinesterase Levels in A549 Cell Media and Apoptosis in a p53-Dependent Manner. Sci. Rep. 2020, 10, 5083. [Google Scholar] [CrossRef] [Green Version]
- Perez-Aguilar, B.; Vidal, C.J.; Palomec, G.; Garcia-Dolores, F.; Gutierrez-Ruiz, M.C.; Bucio, L.; Gomez-Olivares, J.L.; Gomez-Quiroz, L.E. Acetylcholinesterase is associated with a decrease in cell proliferation of hepatocellular carcinoma cells. Biochim. Biophys. Acta 2015, 1852, 1380–1387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Calaf, G.M.; Parra, E.; Garrido, F. Cell proliferation and tumor formation induced by eserine, an acetylcholinesterase inhibitor, in rat mammary gland. Oncol. Rep. 2007, 17, 25–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Calaf, G.M. Role of organophosphorous pesticides and acetylcholine in breast carcinogenesis. Semin. Cancer Biol. 2021. [Google Scholar] [CrossRef]
- Raufman, J.P.; Samimi, R.; Shah, N.; Khurana, S.; Shant, J.; Drachenberg, C.; Xie, G.; Wess, J.; Cheng, K. Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res. 2008, 68, 3573–3578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shah, N.; Khurana, S.; Cheng, K.; Raufman, J.P. Muscarinic receptors and ligands in cancer. Am. J. Physiol. Cell Physiol. 2009, 296, C221–C232. [Google Scholar] [CrossRef] [Green Version]
- Elie, J.; Feizbakhsh, O.; Desban, N.; Josselin, B.; Baratte, B.; Bescond, A.; Duez, J.; Fant, X.; Bach, S.; Marie, D.; et al. Design of new disubstituted imidazo[1,2-b]pyridazine derivatives as selective Haspin inhibitors. Synthesis, binding mode and anticancer biological evaluation. J. Enzyme. Inhib. Med. Chem. 2020, 35, 1840–1853. [Google Scholar] [CrossRef]
- Chen, Y.; Bai, G.; Ning, Y.; Cai, S.; Zhang, T.; Song, P.; Zhou, J.; Duan, W.; Ding, J.; Xie, H.; et al. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. Eur. J. Med. Chem. 2020, 190, 112092. [Google Scholar] [CrossRef] [PubMed]
- Colombano, G.; Caldwell, J.J.; Matthews, T.P.; Bhatia, C.; Joshi, A.; McHardy, T.; Mok, N.Y.; Newbatt, Y.; Pickard, L.; Strover, J.; et al. Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1alpha Kinase-Endoribonuclease. J. Med. Chem. 2019, 62, 2447–2465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ewida, M.A.; Abou El Ella, D.A.; Lasheen, D.S.; Ewida, H.A.; El-Gazzar, Y.I.; El-Subbagh, H.I. Imidazo[2’,1’:2,3]thiazolo[4,5-d]pyridazinone as a new scaffold of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study. Bioorg. Chem. 2018, 80, 11–23. [Google Scholar] [CrossRef] [PubMed]
- Bu, H.; Yuan, X.; Wu, H.; Zhou, J.; Zhang, H. Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors. Bioorg. Med. Chem. 2021, 40, 116186. [Google Scholar] [CrossRef]
- Schepetkin, I.A.; Plotnikov, M.B.; Khlebnikov, A.I.; Plotnikova, T.M.; Quinn, M.T. Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential. Biomolecules 2021, 11, 777. [Google Scholar] [CrossRef] [PubMed]
- Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J. Toxicol. Clin. Toxicol. 2002, 40, 803–816. [Google Scholar] [CrossRef]
- Moine, E.; Moire, N.; Dimier-Poisson, I.; Brunet, K.; Couet, W.; Colas, C.; Van Langendonck, N.; Enguehard-Gueiffier, C.; Gueiffier, A.; Heraut, B.; et al. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis. Int. J. Parasitol. 2018, 48, 561–568. [Google Scholar] [CrossRef]
- Cheuka, P.M.; Lawrence, N.; Taylor, D.; Wittlin, S.; Chibale, K. Antiplasmodial imidazopyridazines: Structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles. Medchemcomm 2018, 9, 1733–1745. [Google Scholar] [CrossRef]
- Green, J.L.; Moon, R.W.; Whalley, D.; Bowyer, P.W.; Wallace, C.; Rochani, A.; Nageshan, R.K.; Howell, S.A.; Grainger, M.; Jones, H.M.; et al. Imidazopyridazine Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinase 1 Also Target Cyclic GMP-Dependent Protein Kinase and Heat Shock Protein 90 To Kill the Parasite at Different Stages of Intracellular Development. Antimicrob. Agents Chemother. 2015, 60, 1464–1475. [Google Scholar] [CrossRef] [Green Version]
- Kaieda, A.; Takahashi, M.; Takai, T.; Goto, M.; Miyazaki, T.; Hori, Y.; Unno, S.; Kawamoto, T.; Tanaka, T.; Itono, S.; et al. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Bioorg. Med. Chem. 2018, 26, 647–660. [Google Scholar] [CrossRef]
- Rimoli, M.G.; Russo, E.; Cataldi, M.; Citraro, R.; Ambrosino, P.; Melisi, D.; Curcio, A.; De Lucia, S.; Patrignani, P.; De Sarro, G.; et al. T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. Neuropharmacology 2009, 56, 637–646. [Google Scholar] [CrossRef]
- Palazzo, E.; Rimoli, M.G.; De Chiaro, M.; Guida, F.; Melisi, D.; Curcio, A.; de Novellis, V.; Marabese, I.; Rossi, F.; Abignente, E.; et al. Intra-periaqueductal grey microinjections of an imidazo[1,2-b]pyridazine derivative, DM2, affects rostral ventromedial medulla cell activity and shows antinociceptive effect. Neuropharmacology 2010, 58, 660–667. [Google Scholar] [CrossRef] [PubMed]
- Shimizu, H.; Yamasaki, T.; Yoneda, Y.; Muro, F.; Hamada, T.; Yasukochi, T.; Tanaka, S.; Toki, T.; Yokoyama, M.; Morishita, K.; et al. Discovery of imidazo[1,2-b]pyridazines as IKKbeta inhibitors. Part 3: Exploration of effective compounds in arthritis models. Bioorg. Med. Chem. Lett. 2011, 21, 4550–4555. [Google Scholar] [CrossRef] [PubMed]
- Mao, B.; Gao, S.; Weng, Y.; Zhang, L.; Zhang, L. Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors. Eur. J. Med. Chem. 2017, 129, 135–150. [Google Scholar] [CrossRef]
- Jiang, Y.; Yau, M.K.; Lim, J.; Wu, K.C.; Xu, W.; Suen, J.Y.; Fairlie, D.P. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J. Pharmacol. Exp. Ther. 2018, 364, 246–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyamoto, N.; Sakai, N.; Hirayama, T.; Miwa, K.; Oguro, Y.; Oki, H.; Okada, K.; Takagi, T.; Iwata, H.; Awazu, Y.; et al. Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylph enyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor. Bioorg. Med. Chem. 2013, 21, 2333–2345. [Google Scholar] [CrossRef]
- Kusakabe, K.; Ide, N.; Daigo, Y.; Itoh, T.; Yamamoto, T.; Hashizume, H.; Nozu, K.; Yoshida, H.; Tadano, G.; Tagashira, S.; et al. Discovery of imidazo[1,2-b]pyridazine derivatives: Selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J. Med. Chem. 2015, 58, 1760–1775. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.S.; Redkar, S.; Taverna, P.; Cortes, J.E.; Gandhi, V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011, 118, 693–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, C.; Lin, J.; Moslin, R.; Tokarski, J.S.; Muckelbauer, J.; Chang, C.; Tredup, J.; Xie, D.; Park, H.; Li, P.; et al. Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Med. Chem. Lett. 2019, 10, 383–388. [Google Scholar] [CrossRef] [PubMed]
- Choi, H.S.; Rucker, P.V.; Wang, Z.; Fan, Y.; Albaugh, P.; Chopiuk, G.; Gessier, F.; Sun, F.; Adrian, F.; Liu, G.; et al. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med. Chem. Lett. 2015, 6, 562–567. [Google Scholar] [CrossRef] [Green Version]
- Sawaguchi, Y.; Yamazaki, R.; Nishiyama, Y.; Mae, M.; Abe, A.; Nishiyama, H.; Nishisaka, F.; Ibuki, T.; Sasai, T.; Matsuzaki, T. Novel Pan-Pim Kinase Inhibitors with Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities. Front. Pharmacol. 2021, 12, 672536. [Google Scholar] [CrossRef]
- Cheuka, P.M.; Centani, L.; Arendse, L.B.; Fienberg, S.; Wambua, L.; Renga, S.S.; Dziwornu, G.A.; Kumar, M.; Lawrence, N.; Taylor, D.; et al. New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP-Dependent Protein Kinase. ACS Infect. Dis. 2021, 7, 34–46. [Google Scholar] [CrossRef] [PubMed]
- Shakil, S. Molecular interaction of anti-cancer ligands with human brain acetylcholinesterase. J. Biomol. Struct. Dyn. 2020, 1–10. [Google Scholar] [CrossRef]
- Guo, J.; Cheng, J.; North, B.J.; Wei, W. Functional analyses of major cancer-related signaling pathways in Alzheimer’s disease etiology. Biochim. Biophys. Acta Rev. Cancer 2017, 1868, 341–358. [Google Scholar] [CrossRef]
- Krall, J.; Bavo, F.; Falk-Petersen, C.B.; Jensen, C.H.; Nielsen, J.O.; Tian, Y.; Anglani, V.; Kongstad, K.T.; Piilgaard, L.; Nielsen, B.; et al. Discovery of 2-(Imidazo[1,2- b]pyridazin-2-yl)acetic Acid as a New Class of Ligands Selective for the gamma-Hydroxybutyric Acid (GHB) High-Affinity Binding Sites. J. Med. Chem. 2019, 62, 2798–2813. [Google Scholar] [CrossRef]
- Fushimi, M.; Fujimori, I.; Wakabayashi, T.; Hasui, T.; Kawakita, Y.; Imamura, K.; Kato, T.; Murakami, M.; Ishii, T.; Kikko, Y.; et al. Discovery of Potent, Selective, and Brain-Penetrant 1 H-Pyrazol-5-yl-1 H-pyrrolo[2,3- b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors. J. Med. Chem. 2019, 62, 4915–4935. [Google Scholar] [CrossRef] [PubMed]
- Akundi, R.S.; Zhi, L.; Sullivan, P.G.; Bueler, H. Shared and cell type-specific mitochondrial defects and metabolic adaptations in primary cells from PINK1-deficient mice. Neurodegener. Dis. 2013, 12, 136–149. [Google Scholar] [CrossRef] [PubMed]
- Riccardi, C.; Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 2006, 1, 1458–1461. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sharma, R.K.; Singh, M.; Ghimeray, K.; Juneja, P.; Dev, G.; Pulavarthi, S.; Reddy, S.R.; Akundi, R.S. Imidazopyridazine Acetylcholinesterase Inhibitors Display Potent Anti-Proliferative Effects in the Human Neuroblastoma Cell-Line, IMR-32. Molecules 2021, 26, 5319. https://doi.org/10.3390/molecules26175319
Sharma RK, Singh M, Ghimeray K, Juneja P, Dev G, Pulavarthi S, Reddy SR, Akundi RS. Imidazopyridazine Acetylcholinesterase Inhibitors Display Potent Anti-Proliferative Effects in the Human Neuroblastoma Cell-Line, IMR-32. Molecules. 2021; 26(17):5319. https://doi.org/10.3390/molecules26175319
Chicago/Turabian StyleSharma, Rakesh Kumar, Manisha Singh, Khagendra Ghimeray, Pinky Juneja, Gagan Dev, Sridhar Pulavarthi, Sabbasani Rajasekhara Reddy, and Ravi Shankar Akundi. 2021. "Imidazopyridazine Acetylcholinesterase Inhibitors Display Potent Anti-Proliferative Effects in the Human Neuroblastoma Cell-Line, IMR-32" Molecules 26, no. 17: 5319. https://doi.org/10.3390/molecules26175319